Estudo do potencial terapêutico do ácido betulínico no tratamento de dislipidemia e diabetes em camundongos

• Ano de defesa: 2012
• Autor(a) principal: Dantas, Mariana Brito
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Palavras-chave em Português: Diabetes Mellitus; Dislipidemias; Triterpenos
• Link de acesso: http://www.repositorio.ufc.br/handle/riufc/4217

Diabetes and dyslipidemia prevalence has been increasing globally configured as an epidemic resultant mainly from overweight, physical inactivity and genetic susceptibility. There are reports of many natural products that have hypoglycemic and hypolipidemic activity. Among them we mention the terpenes, which are the largest group of secondary products of plants metabolism. The terpene studied in this work was betulinic acid (BA), a pentacyclic triterpene lupano type that presents a variety of biological and pharmacological activities. The objective of this study was to evaluate BA hypoglycemic and hypolipidemic effects in experimental protocols of dyslipidemia and diabetes induced pharmacologically as well as studying their toxic potential in vivo. The BA-treated groups received doses of 5 (BA5), 10 (BA10) and 20 (BA20) mg/kg. The evaluation of the BA hypoglycemic action was carried out through diabetes induced by alloxan protocol and oral glucose tolerance test (OGTT). To check their activity on lipid metabolism, it was carried out dyslipidemia protocol induced by Triton WR 1339 intraperitoneal injection. In addition, it was performed the protocol modified diet-induced hypercholesterolemia. Toxicity was assessed by the study repeated doses for 28 days treating daily with BA doses via gavage. After the protocol of alloxan-induced diabetes, there was a blood glucose reduction in groups BA10 and BA20. Triglycerides and total cholesterol decreased significantly at all doses studied. BA10 treatment, also reduced the blood glucose peak caused by glucose overload (2g/Kg) in the OGTT. After 24 hours of dyslipidemia induced by triton, there was a significant triglycerides reduction in groups treated with BA at doses of 10 and 20mg/Kg. After 48h, triglycerides levels remained reduced in group treated with BA10. In hypercholesterolemia induced by diet modified protocol BA at doses of 10 and 20mg/kg, promoted a significant decrease in total cholesterol levels. There were no significant changes in the parameters evaluated after repeated dose oral toxicity protocol. Results demonstrate the therapeutic potential and safety of betulinic acid in the treatment of dyslipidemia and diabetes, although others pre-clinical and clinical studies are necessary for its use by population.